TBC1D2

Summary

TBC1D2 (TBC1 domain family member 2, HGNC:18026) is a protein-coding gene on chromosome 9q22.33, encoding TBC1 domain family member 2A (Q9BYX2). Acts as a GTPase-activating protein for RAB7A.

Enables GTPase activator activity and cadherin binding activity. Involved in positive regulation of GTPase activity. Located in several cellular components, including cytoplasmic vesicle; cytosol; and nucleoplasm.

Source: NCBI Gene 55357 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 165 total
• MANE Select transcript: NM_001267571

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18026
Approved symbol	TBC1D2
Name	TBC1 domain family member 2
Location	9q22.33
Locus type	gene with protein product
Status	Approved
Aliases	PARIS1, TBC1D2A, Armus
Ensembl gene	ENSG00000095383
Ensembl biotype	protein_coding
OMIM	609871
Entrez	55357

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000342112, ENST00000375063, ENST00000375064, ENST00000375066, ENST00000465784, ENST00000493589

RefSeq mRNA: 4 — MANE Select: NM_001267571 NM_001267571, NM_001267572, NM_001410988, NM_018421

CCDS: CCDS35080, CCDS59137, CCDS75865, CCDS94445

Canonical transcript exons

ENST00000465784 — 13 exons

Exon	Start	End
ENSE00001850033	98255173	98255649
ENSE00003583641	98243994	98244129
ENSE00003751770	98199011	98199588
ENSE00003888754	98251785	98251926
ENSE00003889138	98213108	98213218
ENSE00003889246	98200253	98200374
ENSE00003889412	98228952	98229148
ENSE00003892162	98220833	98221228
ENSE00003892847	98208668	98209144
ENSE00003893117	98203288	98203408
ENSE00003894452	98210656	98210843
ENSE00003895442	98201479	98201664
ENSE00003896218	98233416	98233549

Expression profiles

Bgee: expression breadth ubiquitous, 243 present calls, max score 91.11.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 15.8033 / max 180.9976, expressed in 1712 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
101679	5.1600	1388
101678	3.4847	878
101680	3.4497	1267
101676	3.1698	688
101677	0.5391	324

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	91.11	gold quality
upper lobe of left lung	UBERON:0008952	91.05	gold quality
mononuclear cell	CL:0000842	90.89	gold quality
leukocyte	CL:0000738	90.63	gold quality
upper lobe of lung	UBERON:0008948	90.45	gold quality
esophagus mucosa	UBERON:0002469	89.93	gold quality
granulocyte	CL:0000094	88.66	gold quality
right lung	UBERON:0002167	88.27	gold quality
gingival epithelium	UBERON:0001949	88.00	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	87.27	gold quality
mucosa of transverse colon	UBERON:0004991	87.22	gold quality
stromal cell of endometrium	CL:0002255	87.12	gold quality
lower esophagus mucosa	UBERON:0035834	86.98	gold quality
skin of leg	UBERON:0001511	86.53	gold quality
gingiva	UBERON:0001828	86.01	gold quality
skin of abdomen	UBERON:0001416	85.89	gold quality
blood	UBERON:0000178	85.47	gold quality
spinal cord	UBERON:0002240	84.86	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	84.34	gold quality
zone of skin	UBERON:0000014	83.90	gold quality
lung	UBERON:0002048	83.75	gold quality
right lobe of liver	UBERON:0001114	83.35	gold quality
minor salivary gland	UBERON:0001830	82.12	gold quality
decidua	UBERON:0002450	82.05	gold quality
esophagus	UBERON:0001043	82.04	gold quality
mouth mucosa	UBERON:0003729	82.04	gold quality
vagina	UBERON:0000996	81.64	gold quality
tibial nerve	UBERON:0001323	80.21	gold quality
saliva-secreting gland	UBERON:0001044	80.10	gold quality
epithelium of esophagus	UBERON:0001976	79.68	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.85
E-MTAB-6075	no	11.07

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

47 targeting TBC1D2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-302A-3P	99.89	71.23	1777
HSA-MIR-302B-3P	99.89	71.23	1777
HSA-MIR-302C-3P	99.89	71.20	1778
HSA-MIR-302D-3P	99.89	71.25	1777
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-526B-3P	99.88	74.06	2587
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-519D-3P	99.88	73.97	2607
HSA-MIR-93-5P	99.88	73.98	2606
HSA-MIR-373-3P	99.84	70.68	1668
HSA-MIR-520E-3P	99.84	70.55	1698
HSA-MIR-372-3P	99.83	70.58	1691
HSA-MIR-520A-3P	99.83	70.59	1687
HSA-MIR-520B-3P	99.83	70.56	1699
HSA-MIR-520C-3P	99.83	70.56	1699
HSA-MIR-520D-3P	99.83	70.78	1676
HSA-MIR-370-5P	99.78	66.81	706
HSA-MIR-452-5P	99.65	69.63	1762
HSA-MIR-4676-3P	99.65	69.31	1733
HSA-MIR-892C-3P	99.65	69.38	1745
HSA-MIR-3123	99.47	67.15	2693
HSA-MIR-4251	99.40	69.19	3363

Literature-anchored findings (GeneRIF, showing 3)

• integration of Rac1 and Rab7 activities by Armus provides an important regulatory node for E-cadherin turnover and stability of cell-cell contacts (PMID:20116244)
• TBC1D2/Armus, a GAP of Rab7 GTPase, is reported as a novel target of miR-17. (PMID:23285084)
• Armus expression induces autophagosome accumulation in keratinocytes. (PMID:23562278)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	tbc1d2	ENSDARG00000071304
mus_musculus	Tbc1d2	ENSMUSG00000039813
rattus_norvegicus	Tbc1d2	ENSRNOG00000023348

Paralogs (45): RABGAP1 (ENSG00000011454), TBC1D22A (ENSG00000054611), TBC1D22B (ENSG00000065491), TBC1D1 (ENSG00000065882), EVI5 (ENSG00000067208), TBC1D25 (ENSG00000068354), TBC1D10A (ENSG00000099992), SGSM3 (ENSG00000100359), TBC1D17 (ENSG00000104946), TBC1D13 (ENSG00000107021), TBC1D12 (ENSG00000108239), TBC1D9 (ENSG00000109436), TBC1D30 (ENSG00000111490), TBC1D15 (ENSG00000121749), TBC1D5 (ENSG00000131374), TBC1D14 (ENSG00000132405), TBC1D8B (ENSG00000133138), TBC1D4 (ENSG00000136111), GRTP1 (ENSG00000139835), SGSM2 (ENSG00000141258), EVI5L (ENSG00000142459), TBCK (ENSG00000145348), USP6NL (ENSG00000148429), RABGAP1L (ENSG00000152061), SGSM1 (ENSG00000167037), TBC1D21 (ENSG00000167139), TBC1D2B (ENSG00000167202), TBC1D16 (ENSG00000167291), TBC1D10B (ENSG00000169221), TBC1D10C (ENSG00000175463), TBC1D28 (ENSG00000189375), TBC1D9B (ENSG00000197226), TBC1D8 (ENSG00000204634), TBC1D26 (ENSG00000214946), TBC1D3G (ENSG00000260287), TBC1D3K (ENSG00000273513), TBC1D3H (ENSG00000274226), TBC1D3D (ENSG00000274419), TBC1D3L (ENSG00000274512), TBC1D3 (ENSG00000274611)

Protein

Protein identifiers

TBC1 domain family member 2A — Q9BYX2 (reviewed: Q9BYX2)

Alternative names: Armus, Prostate antigen recognized and identified by SEREX 1

All UniProt accessions (1): Q9BYX2

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a GTPase-activating protein for RAB7A. Signal effector acting as a linker between RAC1 and RAB7A, leading to RAB7A inactivation and subsequent inhibition of cadherin degradation and reduced cell-cell adhesion.

Subunit / interactions. Interacts with activated RAC1 and CDH1.

Subcellular location. Cytoplasm. Cytoplasmic vesicle. Cell junction.

Tissue specificity. Expressed in a broad range of tissues, especially in kidney, liver, lung and placenta. Also expressed in keratinocytes and epithelia-containing organs. Isoform 2 is differentially expressed in prostate normal and cancer cells (at protein level).

Miscellaneous. ‘Armus’ means hinge, linker in Latin and ancient Greek.

Isoforms (6)

UniProt ID	Names	Canonical?
Q9BYX2-1	1, A variant C	yes
Q9BYX2-2	2, PARIS-1
Q9BYX2-3	3, A
Q9BYX2-4	4
Q9BYX2-5	5
Q9BYX2-6	6

RefSeq proteins (4): NP_001254500, NP_001254501, NP_001397917, NP_060891 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000195	Rab-GAP-TBC_dom	Domain
IPR001849	PH_domain	Domain
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR035969	Rab-GAP_TBC_sf	Homologous_superfamily
IPR050302	Rab_GAP_TBC_domain	Family

Pfam: PF00169, PF00566

UniProt features (41 total): strand 9, sequence conflict 6, splice variant 5, modified residue 4, region of interest 4, sequence variant 3, helix 3, domain 2, coiled-coil region 2, chain 1, turn 1, compositionally biased region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2DHK	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BYX2-F1	75.94	0.39

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 1, 436, 915, 920

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-8854214	TBC/RABGAPs
R-HSA-199991	Membrane Trafficking
R-HSA-5653656	Vesicle-mediated transport
R-HSA-9007101	Rab regulation of trafficking

MSigDB gene sets: 150 (showing top): BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOZGIT_ESR1_TARGETS_DN, GOBP_REGULATION_OF_GTPASE_ACTIVITY, REACTOME_MEMBRANE_TRAFFICKING, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY, GOBP_REGULATION_OF_HYDROLASE_ACTIVITY, RICKMAN_METASTASIS_DN, GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION, GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION, KOYAMA_SEMA3B_TARGETS_UP, BLALOCK_ALZHEIMERS_DISEASE_UP, GOBP_CILIUM_ORGANIZATION, GOBP_ORGANELLE_ASSEMBLY, ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN

GO Biological Process (1): positive regulation of GTPase activity (GO:0043547)

GO Molecular Function (3): GTPase activator activity (GO:0005096), cadherin binding (GO:0045296), protein binding (GO:0005515)

GO Cellular Component (7): nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829), plasma membrane (GO:0005886), cell junction (GO:0030054), cytoplasmic vesicle (GO:0031410), anchoring junction (GO:0070161)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Rab regulation of trafficking	1
Vesicle-mediated transport	1
Membrane Trafficking	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
GTPase activity	2
cytoplasm	2
regulation of GTPase activity	1
positive regulation of hydrolase activity	1
enzyme activator activity	1
GTPase regulator activity	1
cell adhesion molecule binding	1
binding	1
nuclear lumen	1
intracellular anatomical structure	1
membrane	1
cell periphery	1
intracellular vesicle	1
cell junction	1

Protein interactions and networks

STRING

1598 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TBC1D2	TBC1D15	Q8TC07	696
TBC1D2	TBC1D5	Q92609	642
TBC1D2	VAMP7	P51809	551
TBC1D2	TBC1D25	Q3MII6	550
TBC1D2	CDC16	Q13042	526
TBC1D2	LRRK1	Q38SD2	508
TBC1D2	TBC1D20	Q96BZ9	486
TBC1D2	TBC1D19	Q8N5T2	477
TBC1D2	RAB5A	P20339	473
TBC1D2	TBC1D21	Q8IYX1	466
TBC1D2	TBC1D13	Q9NVG8	464
TBC1D2	CCZ1B	P86790	454
TBC1D2	MON1A	Q86VX9	432
TBC1D2	PIK3C3	Q8NEB9	429
TBC1D2	GABARAP	O95166	418

IntAct

15 interactions, top by confidence:

A	B	Type	Score
	TK2	psi-mi:“MI:0915”(physical association)	0.400
TBC1D2	CDC42	psi-mi:“MI:0915”(physical association)	0.370
AURKA	TBC1D2	psi-mi:“MI:0915”(physical association)	0.370
BUB1	TBC1D2	psi-mi:“MI:0915”(physical association)	0.370
TBC1D2	CCND1	psi-mi:“MI:0915”(physical association)	0.370
DCC	TBC1D2	psi-mi:“MI:0915”(physical association)	0.370
TBC1D2	MLH3	psi-mi:“MI:0915”(physical association)	0.370
TBC1D2	PDGFRL	psi-mi:“MI:0915”(physical association)	0.370
KRT40	ANKRD36	psi-mi:“MI:0914”(association)	0.350
TBC1D2	HMMR	psi-mi:“MI:0914”(association)	0.350
ZBTB43	SPINDOC	psi-mi:“MI:0914”(association)	0.350
KRT40	NEURL1B	psi-mi:“MI:0914”(association)	0.350
RBBP4	PHF20L1	psi-mi:“MI:0914”(association)	0.350

BioGRID (41): TBC1D2 (Affinity Capture-MS), TBC1D2 (Affinity Capture-MS), KCTD6 (Two-hybrid), TBC1D2 (Two-hybrid), TBC1D2 (Two-hybrid), TBC1D2 (Two-hybrid), TBC1D2 (Two-hybrid), TBC1D2 (Two-hybrid), TBC1D2 (Two-hybrid), TBC1D2 (Proximity Label-MS), TBC1D2 (Affinity Capture-MS), WBP5 (Affinity Capture-MS), SASS6 (Affinity Capture-MS), TBC1D2 (Affinity Capture-MS), FAM83D (Affinity Capture-MS)

ESM2 similar proteins: A0A8I3NFE2, A0FI79, B1AVH7, B5DFA1, D2H0G5, D7PF45, O00750, O15357, O70143, P29353, P97573, P98083, Q00IB7, Q0IIE2, Q15678, Q16825, Q17R13, Q2I6J0, Q2I6J1, Q2V2M9, Q5JV73, Q5M824, Q5R7W7, Q5U2X5, Q61120, Q62130, Q62136, Q62728, Q62925, Q69Z98, Q6P4S2, Q6P549, Q80TI1, Q8AY68, Q8BMC3, Q8BYW1, Q8IWQ3, Q8K245, Q92529, Q92835

Diamond homologs: A2AWA9, A3KGB4, A6H6A9, A6H8I2, A6QP29, B0R0W9, B1AVH7, B5DFA1, C8VDQ4, D2H0G5, F4HVW5, O60447, O95759, P53258, P58802, P87234, Q0IIM8, Q12317, Q28CB1, Q2KI13, Q3KR37, Q3KR56, Q3U0J8, Q3UYK3, Q4KMP7, Q4QQU7, Q5R372, Q5RAN1, Q5RCW6, Q5SVR0, Q5TC63, Q66K14, Q6C8M8, Q6GL87, Q6GLZ0, Q6P6R7, Q6PBU5, Q6ZT07, Q7T2D0, Q80TI0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

165 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	126
Likely benign	13
Benign	8

Top pathogenic / likely-pathogenic (0)

SpliceAI

2166 predictions. Top by Δscore:

Variant	Effect	Δscore
9:98199585:CTTC:C	acceptor_gain	1.0000
9:98199586:TTCCT:T	acceptor_loss	1.0000
9:98199587:TCCT:T	acceptor_loss	1.0000
9:98199588:CCT:C	acceptor_loss	1.0000
9:98199589:C:CC	acceptor_gain	1.0000
9:98199590:T:A	acceptor_loss	1.0000
9:98200247:CCT:C	donor_loss	1.0000
9:98200248:CTCA:C	donor_loss	1.0000
9:98200249:TCACC:T	donor_loss	1.0000
9:98200250:CA:C	donor_loss	1.0000
9:98200251:A:AC	donor_gain	1.0000
9:98200251:ACC:A	donor_loss	1.0000
9:98200252:C:CC	donor_gain	1.0000
9:98200252:C:T	donor_loss	1.0000
9:98200252:CCGG:C	donor_gain	1.0000
9:98200370:ACCAC:A	acceptor_gain	1.0000
9:98200371:CCAC:C	acceptor_gain	1.0000
9:98200371:CCACC:C	acceptor_gain	1.0000
9:98200372:CAC:C	acceptor_gain	1.0000
9:98200372:CACC:C	acceptor_gain	1.0000
9:98200373:ACC:A	acceptor_loss	1.0000
9:98200374:CCT:C	acceptor_loss	1.0000
9:98200375:C:CC	acceptor_gain	1.0000
9:98200375:CTG:C	acceptor_loss	1.0000
9:98200376:T:A	acceptor_loss	1.0000
9:98201474:CCTA:C	donor_loss	1.0000
9:98201475:CTAC:C	donor_loss	1.0000
9:98201476:TA:T	donor_loss	1.0000
9:98201477:AC:A	donor_loss	1.0000
9:98201478:CCTTC:C	donor_loss	1.0000

AlphaMissense

6049 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:98251886:A:G	L137P	0.995
9:98251899:A:G	W133R	0.995
9:98251899:A:T	W133R	0.995
9:98255387:A:G	L52S	0.995
9:98255340:A:G	W68R	0.994
9:98255340:A:T	W68R	0.994
9:98255210:A:G	F111S	0.993
9:98255177:A:G	L122P	0.992
9:98255309:A:G	L78P	0.992
9:98255393:C:T	G50E	0.992
9:98251875:G:T	R141S	0.990
9:98251895:A:G	L134P	0.990
9:98201508:A:G	W810R	0.989
9:98201508:A:T	W810R	0.989
9:98251874:C:G	R141P	0.989
9:98251897:C:A	W133C	0.989
9:98251897:C:G	W133C	0.989
9:98255335:G:C	F69L	0.989
9:98255335:G:T	F69L	0.989
9:98255337:A:G	F69L	0.989
9:98255204:A:G	I113T	0.988
9:98255343:G:T	R67S	0.988
9:98208915:A:G	W635R	0.987
9:98208915:A:T	W635R	0.987
9:98243997:A:G	I215T	0.987
9:98220970:C:G	A413P	0.986
9:98255204:A:C	I113S	0.986
9:98255342:C:G	R67P	0.986
9:98255394:C:A	G50W	0.986
9:98255309:A:T	L78Q	0.985

dbSNP variants (sampled 300 via entrez): RS1000079747 (9:98222368 G>T), RS1000115465 (9:98236255 A>G), RS1000140464 (9:98252474 C>G), RS1000153676 (9:98216401 C>T), RS1000191799 (9:98207386 T>C), RS1000193805 (9:98231261 A>G), RS1000235418 (9:98236603 A>G), RS1000365772 (9:98212846 A>G), RS1000415364 (9:98200579 A>C,G), RS1000574539 (9:98230173 C>A), RS1000629048 (9:98223732 G>A), RS1000724151 (9:98254634 C>G,T), RS1000771987 (9:98225123 C>T), RS1000818231 (9:98249647 A>G), RS1000821216 (9:98213141 C>A)

Disease associations

OMIM: gene MIM:609871 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST002963_6	Post-traumatic stress disorder	1.000000e-06
GCST003123_22	Severe influenza A (H1N1) infection	4.000000e-08
GCST009391_1224	Metabolite levels	6.000000e-06
GCST009391_1234	Metabolite levels	2.000000e-06
GCST009557_13	Rate of ventricular enlargement	4.000000e-06
GCST012490_398	Femur bone mineral density x serum urate levels interaction	1.000000e-08

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:1001488	influenza A (H1N1)
EFO:0010421	triacylglycerol 54:3 measurement
EFO:0010422	triacylglycerol 54:4 measurement
EFO:0010570	ventricular enlargement measurement
EFO:0004531	urate measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

56 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	4
Benzo(a)pyrene	affects methylation, decreases methylation, increases mutagenesis	3
bisphenol A	affects cotreatment, increases methylation, decreases methylation, increases expression	2
sodium arsenite	affects cotreatment, decreases expression, increases abundance, increases expression	2
Arsenic	increases expression, affects cotreatment, decreases expression, increases abundance	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
Particulate Matter	decreases expression, increases abundance, affects cotreatment, increases expression	2
aminomethylphosphonic acid (AMPA)	decreases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
glycidyl methacrylate	decreases expression	1
sodium arsenate	increases abundance, increases expression	1
2-methyl-4-isothiazolin-3-one	decreases expression	1
ethyl-p-hydroxybenzoate	increases expression	1
butyraldehyde	increases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
avobenzone	increases expression	1
Am 580	increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, increases expression	1
(+)-JQ1 compound	increases expression	1
Rosiglitazone	increases expression	1
Resveratrol	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.